Glenmark Pharmaceuticals (GPL), a leading Indian multinational pharmaceutical company’s - wholly owned subsidiary - Glenmark Pharmaceuticals S.A (GPSA), has entered into an agreement with Forest Laboratories, Inc., an international health care leader, on collaboration for the development of novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.
Glenmark has identified clinical candidates and is currently conducting pre-clinical studies and other development activities required to support the initiation of first-in-human dosing.
Under the terms of the agreement, Forest will make a $6 million upfront payment to Glenmark and provide an additional $3 million to support the next phase of work. Forest will make other future payments in FY2014 to support the advancement of the ongoing mPGES-1 inhibitors program. Forest has an exclusive option to obtain license rights to the program upon the completion of Phase 1 clinical trials.
Both parties will work collaboratively to advance the program into the clinic. The collaboration between Glenmark and Forest will be managed by a Joint Development Committee with equal representation from both companies.
